Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in zucker diabetic fatty rats with metabolic syndrome

Diabetes, Obesity and Metabolism

Volumn 14, Issue 4, 2012, Pages 320-328

  Rinaldi, B ^a   Di Filippo, C ^a   Capuano, A ^a   Donniacuo, M ^a   Sodano, L ^a   Ferraraccio, F ^a   Rossi, F ^a   D'Amico, M ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Acute myocardial infarction; Cardioprotection; Metabolic syndrome; Telmisartan; ZDF rats

Indexed keywords

ADIPONECTIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; TELMISARTAN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; IMMUNOHISTOCHEMISTRY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; METABOLIC SYNDROME X; NITROSATIVE STRESS; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE LEVEL; TREATMENT DURATION; ZUCKER DIABETIC FATTY RAT;

EID: 84858006294     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01527.x     Document Type: Article

References (58)

1. Eddy DM, Schlessinger L, Heikes K. The metabolic syndrome and cardiovascular risk: implications for clinical practice. Int J Obes (Lond) 2008; 32: S5-10.
2. Gupta A, Gupta V. Metabolic syndrome: what are the risks for humans? Biosci Trends 2010; 4: 204-212.
3. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
4. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136-141.
5. Takeno M, Yasuda S, Otsuka Y, et al. Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction: potential association with C-reactive protein. Circ J 2008; 72: 415-419.
6. Pandey S, Baral N, Majhi S, et al. Prevalence of the metabolic syndrome in acute myocardial infarction and its impact on hospital outcomes. Int J Diabetes Dev Ctries 2009; 29: 52-55.
7. Kim JS, Lee HC, Choi BK, et al. Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation. Diabetes Res Clin Pract 2010; 88: 38-41.
8. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelial-dependent vasodilatation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87: 563-568.
9. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther 2011; 5: 325-380.
10. Hanefeld M, Marx N, Pfutzner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sentivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007; 49: 290-297.
11. Halvorsen B, Heggen E, Ueland T, et al. Treatment with the PPARgamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. Eur J Endocrinol 2010; 162: 267-273.
12. Nakayama S, Watada H, Mita T, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31: 7-13.
13. Derosa G, Fogari E, D'Angelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007; 32: 261-268.
14. Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 2006; 29: 957-961.
15. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007; 7: 463-469.
16. Miura Y, Yamamoto N, Tsunekawa S, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28: 757-758.
17. Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137.
18. Komiya N, Hirose H, Kawabe H, Itoh H, Saito I. Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity. J Atheroscler Thromb 2009; 16: 137-142.
19. Wohl P, Krusinová E, Hill M, et al. Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose. Eur J Endocrinol 2010; 163: 573-583.
20. Tofovic SP, Jackson EK. Rat models of the metabolic syndrome. Methods Mol Med 2003; 86: 29-46.
21. Scarda A, Franzin C, Milan G, et al. Increased adipogenic conversion of muscle satellite cells in obese Zucker rats. Int J Obes (Lond) 2010; 34: 1319-1327.
22. Panchal SK, Brown L. Rodent models for metabolic syndrome research. J Biomed Biotechnol 2011; 2011:351982.
23. Sparks JD, Phung TL, Bolognino M, et al. Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia. Metabolism 1998; 47: 1315-1324.
24. Goyal S, Arora S, Mittal R, et al. Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction. Eur J Pharmacol 2009; 619: 75-84.
25. Baller D, Bretschneider HJ, Hellige G. A critical look at currently used indirect indices of myocardial oxygen consumption. Basic Res Cardiol 1981; 76: 163-181.
26. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001; 60: 329-339.
27. Tsao TS, Tomas E, Murrey HE, et al. Role of disulfide bonds in Acrp30/adiponectin structure and signalling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 2003; 278: 50810-50817.
28. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 2007; 18: 63-70.
29. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J 2009; 73: 608-614.
30. Stefan N, Stumvoll M. Adiponectin-its role in metabolism and beyond. Horm Metab Res 2002; 34: 469-474.
31. Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003; 88: 3236-3240.
32. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 2006; 48: 51-57.
33. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
34. Yamaguchi M, Nakagawa T. Change in lipid components in the adipose and liver tissues of regucalcin transgenic rats with increasing age: suppression of leptin and adiponectin gene expression. Int J Mol Med 2007; 20: 323-328.
35. Kumada M, Kihara S, Sumitsuji S, et al. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.
36. Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234.
37. Trujillo ME, Scherer PE. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167-175.
38. Huang SS, Huang PH, Chen YH, Chiang KH, Chen JW, Lin SJ. Association of adiponectin with future cardiovascular events in patients after acute myocardial infarction. J Atheroscler Thromb 2010; 17: 295-303.
39. Piestrzeniewicz K, Luczak K, Komorowski J, et al. Obesity and adiponectin in acute myocardial infarction. Cardiol J 2007; 14: 29-36.
40. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11: 1096-1103.
41. Tao L, Gao E, Jiao X. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007; 115: 1408-1416.
42. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-737.
43. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998-1007.
44. Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-1663.
45. Yang B, Brown KK, Chen L, et al. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacol 2004; 4: 23.
46. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma- modulating activity. Hypertension 2004; 43: 993-1002.
47. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension 2008; 51: 8-14.
48. Goyal SN, Bharti S, Bhatia J, Nag TC, Ray R, Arya DS. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes. Diabetes Obes Metab 2011; 13: 533-541.
49. Zhu X, Bagchi A, Zhao H, et al. Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction. Crit Care Med 2007; 35: 886-892.
50. Hori M, Nishida K. Toll-like receptor signaling: defensive or offensive for the heart? Circ Res 2008; 102: 137-139.
51. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008; 58: 88-111.
52. Riad A, Jäger S, Sobirey M, et al. Toll-like receptor-4 modulates survival by induction of left ventricular remodelling after myocardial infarction in mice. J Immunol 2008; 180: 6954-6961.
53. Shishido T, Nozaki N, Yamaguchi S, et al. Toll-like receptor-2 modulates ventricular remodelling after myocardial infarction. Circulation 2003; 108: 2905-2910.
54. Himes RW, Smith CW. Tlr2 is critical for diet-induced metabolic syndrome in a murine model. FASEB J 2009; 24: 731-739.
55. Otani H. The role of nitric oxide in myocardial repair and remodelling. Antioxid Redox Signal 2009; 11: 1913-1928.
56. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004; 316: 924-929.
57. Vitseva OI, Tanriverdi K, Tchkonia TT, et al. Inducible toll-like receptor and NF-kappaB regulatory pathway expression in human adipose tissue. Obesity 2008; 16: 932-937.
58. Ajuwon KM, Banz W, Winters TA. Stimulation with peptidoglycan induces interleukin 6 and TLR2 expression and a concomitant downregulation of expression of adiponectin receptors 1 and 2 in 3T3-L1 adipocytes. J Inflamm 2009; 6: 6-8.